SEQUOIA Trial: Updates from ASH 2024

Opinion
Video

Experts review the 5-year results of the phase 3 SEQUOIA trial evaluating treatment options for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma at the 66th American Society of Hematology Annual Meeting and Exposition 2024.

Current Time 0:00
Duration 9:00
Loaded: 0%
Stream Type LIVE
Remaining Time 9:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Newsletter

    Stay up to date on practice-changing data in community practice.

    Subscribe Now!
    Recent Videos
    1 expert is featured in this series.
    Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring
    3 experts are featured in this series.
    Personalized JAK Inhibitor Selection in Myelofibrosis: Clinical Characteristics, Molecular Profiles, and Treatment Sequencing
    3 experts are featured in this series.
    Advancing Treatment Paradigms in Myeloproliferative Neoplasms: From Molecular Pathogenesis to Patient-Tailored Therapy
    Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease_
    Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease_
    The Evolving Landscape of Myelofibrosis: Current Understanding and Clinical Patterns
    The Evolving Landscape of Myelofibrosis: Current Understanding and Clinical Patterns
    Insights from COCOON: Prophylactic Dermatologic Management With Amivantamab + Lazertinib in Advanced NSCLC
    Insights from COCOON: Prophylactic Dermatologic Management With Amivantamab + Lazertinib in Advanced NSCLC
    1L Treatment for Advanced NSCLC
    1L Treatment for Advanced NSCLC
    3 experts are featured in this series.
    Recap: ELCC 2025 Highlights
    3 experts are featured in this series.
    Presented at ELCC 2025: Key Takeaways From KRYSTAL-7
    3 experts are featured in this series.
    ELCC 2025: Insights From the MARIPOSA Study
    Related Content
    Analysis Illuminates CAR T-Cell Optimization for CLL

    Analysis Illuminates CAR T-Cell Optimization for CLL

    Morgan Bayer
    April 17th 2025
    Article

    Fewer prior therapies with liso-cel in chronic lymphocytic leukemia showed improved overall response rate in TRANSCEND-CLL-004 analysis.

    Read More

    Understanding the Role of Zanubrutinib for the Treatment of CLL

    Understanding the Role of Zanubrutinib for the Treatment of CLL

    Rohit Gosain, MD;Rahul Gosain, MD
    April 23rd 2024
    Podcast

    Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

    Listen

    Incorporating MRD into Monitoring After Fixed-Duration CLL Treatment

    Incorporating MRD into Monitoring After Fixed-Duration CLL Treatment

    Targeted Oncology Staff
    April 7th 2025
    Article

    During a Case-Based Roundtable® event, John N. Allan, MD, discussed the addition of anti-CD20 antibody and the use of MRD following fixed-duration treatment of chronic lymphocytic leukemia.

    Read More

    Exciting Activity in Chronic Lymphocytic Leukemia

    Exciting Activity in Chronic Lymphocytic Leukemia

    Nichole Tucker;Cyrus M. Khan, MD
    May 31st 2023
    Podcast

    In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

    Listen

    Jacobs and Peers Consider Third-Line Treatment in Relapsed/Refractory CLL

    Jacobs and Peers Consider Third-Line Treatment in Relapsed/Refractory CLL

    Targeted Oncology Staff
    March 14th 2025
    Article

    During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for chronic lymphocytic leukemia.

    Read More

    CRISTALLO Study of Venetoclax/Obinutuzumab Achieves Superior MRD in CLL

    CRISTALLO Study of Venetoclax/Obinutuzumab Achieves Superior MRD in CLL

    Jordyn Sava
    February 20th 2025
    Article

    The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline chronic lymphocytic leukemia therapy.

    Read More